Table 2.
Baseline characteristics of individuals switching from RPV/FTC/TAF
| Overall n = 103 | |
|---|---|
| Gender, n (%) | |
| Cisgender female PWH | 25 (24.3) |
| Cisgender male PWH | 72 (69.9) |
| TGW PWH | 6 (5.8) |
| Age, median [IQR] | 50 [43, 57] |
| Italian born, n (%) | 81 (78.6) |
| Mode of HIV acquisition, n (%) | |
| HE | 37 (35.9) |
| PWID | 13 (12.6) |
| MSM | 39 (37.9) |
| Other/unknown | 13 (12.6) |
| Transfusions | 1 (1.0) |
| Previous AIDS, n (%) | 28 (28.3) |
| CD4 cell/mm3, median [IQR] | 730 [548, 911] |
| CD8 cell/mm3, median [IQR] n = 6 | 634 [457, 878] |
| Duration of previous treatment [months], median [IQR] | 27 [17, 45] |
| Previous therapeutic lines, median [IQR] | 4 [3, 5] |
| Previous virological failure to INSTIs, n (%) | 1 (1) |
| Archived M184V, n (%) | 4 (8.5) |
| Archived K65R, n (%) | 1 (2.1) |
| Comorbidities, n (%) | |
| Without any comorbidity | 12 (11.7) |
| Hypertension | 23 (22.3) |
| Diabetes | 11 (10.7) |
| ASCVD | 11 (10.7) |
| BMI > 30 | 6 (5.8) |
| Dyslipidemia | 41 (39.8) |
| CKD (ClCr < 30 ml/min) | 2 (1.9) |
| Lung disease | 8 (7.8) |
| Solid neoplasm | 6 (5.8) |
| Haematological neoplasm | 1 (1.0) |
| AIDS defining cancer | 2 (1.9) |
| Sexually transmitted infections | 34 (33.0) |
| Previous HBV | 19 (18.4) |
| Chronic HBV | 5 (4.9) |
| Previous HCV | 14 (13.6) |
| Chronic HCV | 1 (1.0) |
| Chronic HDV | 0 (0.0) |
| Cirrhosis | 2 (1.9) |
| Psychiatric disorder | 17 (16.5) |
| Bone disease | 14 (13.6) |
| Neurodegenerative disease | 3 (2.9) |
| Autoimmune disorders | 7 (6.8) |
| Other comorbidities | 15 (14.6) |
| Concomitant medication, n (%) | |
| None | 23 (22.3) |
| Antihypertensive | 25 (24.3) |
| Antiplatelet | 10 (9.7) |
| Anticoagulant | 0 (0.0) |
| Statin | 28 (27.2) |
| Ezetimibe | 2 (1.9) |
| Fibrate | 1 (1.0) |
| Other lipid-lowering agents | 0 (0.0) |
| Chemotherapy | 0 (0.0) |
| Inhalatory lung | 2 (1.9) |
| Proton pump inhibitors | 15 (14.6) |
| Oral antidiabetic | 10 (9.7) |
| Insulin | 2 (1.9) |
| DDAs for hepatitis C | 0 (0.0) |
| Antidepressant | 7 (6.8) |
| Antipsychotic | 4 (3.9) |
| Benzodiazepine | 13 (12.6) |
| Methadone | 1 (1.0) |
| Other drugs active against CNS | 2 (1.9) |
| Bone drugs | 1 (1.0) |
| Immunosuppressants | 5 (4.9) |
| Magnesium | 0 (0.0) |
| Calcium supplements | 2 (1.9) |
| Other supplements | 36 (35.0) |
| Other medications | 39 (37.9) |
| Interactions according to Liverpool Database, n (%) | |
| Yellow | 1 (1.0) |
| Orange | 12 (11.7) |
| Red | 0 (0.0) |
Baseline demographic and clinical characteristics of the subgroup of people with HIV switching from rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). Data are presented as median (interquartile range) or number (percentage), as appropriate
IQR interquartile range; TGW transgender women; HE heterosexual contact; PWID people who inject drugs; MSM men who have sex with men; INSTIs integrase strand transfer inhibitors; ASCVD atherosclerotic cardiovascular disease; BMI body mass index; CKD chronic kidney disease; ClCr creatinine clearance; HBV hepatitis B virus; HCV hepatitis C virus; HDV hepatitis D virus; CNS central nervous system; DAAs direct-acting antivirals